Search

Background: Severe pneumonia caused by coronavirus disease 2019 (COVID‐19) is char‐ acterized by inflammatory lung injury, progressive parenchymal stiffening and consolidation, alveolar and airway collapse, altered vascular permeability, diffuse alveolar damage, and surfactant deficiency. COVID‐19 causes both pneumonia and acute respiratory distress syndrome (COVID‐19 ARDS). COVID‐19 ARDS is characterized by severe refractory hypoxemia and high mortality. De‐ spite extensive research, the treatment of COVID‐19 ARDS is far from satisfactory. Some treatments are recommended for exhibiting some clinically positive impacts on COVID‐19 patients although there are already several drugs in clinical trials, some of which are already demonstrating promising results in addressing COVID‐19. Few studies have demonstrated beneficial effects in non‐COVID‐ 19 ARDS treatment of exogenous surfactant, and there is no evidence‐based, proven method for the procedure of surfactant administration. Aim: The aim of this work is to underline the key role of ATII cells and reduced surfactant levels in COVID-19 ARDS and to emphasize the rational basis for exogenous surfactant therapy in COVID-19 ARDS, providing insight for future research. Methods: In this article, we describe and support via the literature the decision to administer large volumes of surfactant to two patients via bronchoalveolar lavage to maximize its distribution in the respira‐ tory tract. Results: In this study, we report on two cases of COVID‐19 ARDS in patients who have been successfully treated with diluted surfactants by bronchoalveolar lavage, followed by a low‐ dose bolus of surfactant. Conclusion: Combining the administration of diluted, exogenous pulmo‐ nary surfactant via bronchoalveolar lavage along with the standard therapy for SARS‐COV‐2‐induced ARDS may be a promising way of improving the management of ARDS.